Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. - Document - Gale OneFile: Health and Medicine
Retinal Physician : May 2019
Pipeline Report: New entries continue to exceed exits
IJMS | Free Full-Text | Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review. - Document - Gale Academic OneFile
Chengdu Kanghongs' Phase III ophthalmic agent drops 7 points in AMD
An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma | Eye
Molecules | Free Full-Text | Recent Advances in Age-Related Macular Degeneration Therapies
Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration - Chen - Annals of Translational Medicine
The Retina Center
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
Anti VEFG Agents In Retinal Diseases
Phase III Trials in Wet AMD—What's Next?
Pipeline Report: Despite major approvals, the queue gets longer
RetinaToday | Treatment Adherence in Neovascular AMD
Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis | SpringerLink
Retinal Physician - The Phase 3 Clinical Trial of Conbercept for Exudative AMD
New Drugs in the Pipeline for the Management of AMD | IntechOpen
Conbercept was constructed by fusing the the second Ig-like domain of... | Download Scientific Diagram
Phase III Trials in Wet AMD—What's Next?
Emerging Treatments for Neovascular AMD - Retina Today
